ARS Pharmaceuticals, Inc. to Post FY2027 Earnings of $0.16 Per Share, Wedbush Forecasts (NASDAQ:SPRY)

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) – Investment analysts at Wedbush lowered their FY2027 earnings per share estimates for ARS Pharmaceuticals in a research report issued to clients and investors on Thursday, March 9th. Wedbush analyst A. Argyrides now forecasts that the company will post earnings of $0.16 per share for the year, down from their previous forecast of $0.26. Wedbush currently has a “Outperform” rating and a $10.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($1.33) per share.

Several other brokerages have also issued reports on SPRY. SVB Leerink assumed coverage on shares of ARS Pharmaceuticals in a research report on Tuesday, December 13th. They set an “outperform” rating and a $14.00 target price for the company. William Blair initiated coverage on ARS Pharmaceuticals in a research note on Tuesday, January 3rd. They set an “outperform” rating and a $17.00 price objective for the company.

ARS Pharmaceuticals Stock Down 12.4 %

SPRY stock opened at $7.86 on Monday. The firm’s 50-day moving average is $7.72. The stock has a market cap of $283.43 million, a price-to-earnings ratio of -3.25 and a beta of -0.08. ARS Pharmaceuticals has a twelve month low of $2.80 and a twelve month high of $9.23.

About ARS Pharmaceuticals

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.